iRadimed reported quarterly EPS of $0.49, topping the Zacks Consensus Estimate of $0.45 by $0.04, or about 8.9%. Earnings also improved from $0.42 per share a year ago, indicating modest year-over-year growth. The release is positive for company fundamentals but likely limited in broader market impact.
iRadimed reported quarterly EPS of $0.49, topping the Zacks Consensus Estimate of $0.45 by $0.04, or about 8.9%. Earnings also improved from $0.42 per share a year ago, indicating modest year-over-year growth. The release is positive for company fundamentals but likely limited in broader market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.34
Ticker Sentiment
